TITLE

Appling the Screws To the FDA

AUTHOR(S)
Abrams, Sandra Lea
PUB. DATE
November 2004
SOURCE
Investment Dealers' Digest;11/29/2004, Vol. 70 Issue 46, p15
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This article reports that in the wake of the Vioxx scandal, the U.S. Congress is beginning to put the heat on the U.S. Food and Drug Administration (FDA) and its drug approval process. With domestic pharmaceutical sales topping $154.6 billion in 2003, according to the Milken Institute in Santa Monica, California, much is at stake. Whether the FDA's procedures for approving drugs need to be overhauled has become a subject of debate as evidence has emerged that Vioxx, Merck & Co. Inc.'s arthritis drug, exhibited risks of heart attack and stroke long before it was finally pulled from the market in September 2003.
ACCESSION #
15224024

 

Related Articles

  • FDA Green-lights New Type 2 Oral Med. Trecroci, D. // Diabetes Health;Dec2006/Jan2007, Vol. 15 Issue 12, p11 

    The article focuses on the approval of the oral medication Januvia by the U.S. Food and Drug Administration on October 17, 2006. Januvia is manufactured by Merck and Co. and is indicated for use in addition to diet to improve blood sugar levels in patients with type 2 diabetes. It cites the most...

  • Molecule of the Month. Lindsley, Craig W. // Current Topics in Medicinal Chemistry;Nov2008, Vol. 8 Issue 17, p1553 

    The article reports on the decision of pharmaceutical companies to withdraw their application for U.S. Food and Drug Administration (FDA) approval of cannabinoid receptor (CB1) antagonist which is believed to be effective in treating obesity. Clinical trials have shown that the drug is linked to...

  • First in DPP-4 inhibitor class cleared for diabetes.  // Drug Topics;11/20/2006, Vol. 150 Issue 22, p18 

    The article reports on the U.S. Food and Drug Administration's approval of Merck & Co.'s sitagliptin, Januvia, as both a monotherapy and an add-on treatment to improve glycemic control in Type 2 diabetes. According to Merck, sitagliptin inhibits the action of dipeptidyl peptidase-4 and slows...

  • Pharma: Other News To Note.  // BioWorld Today;2/14/2012, Vol. 23 Issue 21, p8 

    the article reports on the approval of Zioptan (tatfluprost ophthalmic solution) from Merck & Co. Inc. by the U.S. Food and Drug Administration (FDA) for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

  • Pharma: Other News To Note.  // BioWorld Today;5/9/2013, Vol. 24 Issue 89, p6 

    The article reports on the acceptance of investigational ragweed pollen sublingual allergy immunotherapy tablet by Merck & Co. Inc. for review by the U.S. Food and Drug Administration (FDA).

  • Merck's Zioptan Joins Prostaglandin Market.  // Review of Ophthalmology;Apr2012, Vol. 19 Issue 4, p114 

    The article reports that the use of Zioptan 0.0015%, an analog ophthalmic solution from Merck & Co. Inc., for reducing elevated intraocular pressure in individuals with ocular hypertension or open-angle glaucoma has been approved by the U.S. Food and Drug Administration (FDA).

  • Merck Wins an Approval.  // Chain Drug Review;4/25/2011, Vol. 33 Issue 8, p218 

    The article reports on the approval of Sylatron, a melanoma treatment from Merck & Co. Inc., by the U.S. Food and Drug Administration (FDA) in 2011.

  • FDA wants cholesterol drug limits. Baker, Sam // Hill;6/13/2011, Vol. 18 Issue 83, p14 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to limit the use of the highest dose of Zocor, a cholesterol drug from Merck & Co. Inc., because of alleged increased risks of muscle damage in 2011.

  • Eye Pressure Medication Gets Approval From the FDA.  // Chain Drug Review;3/26/2012, Vol. 34 Issue 6, p66 

    The article reports on the approval of several medications by the U.S. Food and Drug Administration including eye pressure remover Zioptan from Merck & Co. Inc., head lice remedy Sklice from Sanofi Pasteur SA and Avonex Pen injector for multiple sclerosis from Biogen Idec Inc.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics